FLT3 inhibition as therapy in acute myeloid leukemia: A record of trials and tribulations

Oncologist

Volumn 16, Issue 8, 2011, Pages 1162-1174

  Fathi, Amir T ^a   Chabner, Bruce A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Acute myeloid leukemia; FLT3; Internal tandem duplication; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; KW 2449; LESTAURTINIB; MIDOSTAURIN; PLACEBO; QUIZARTINIB; SEMAXANIB; SORAFENIB; STAT5 PROTEIN; SUNITINIB; TANDUTINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CYTOTOXICITY; DIMERIZATION; DISEASE FREE SURVIVAL; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FATIGUE; GENE DUPLICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IC 50; MUSCLE WEAKNESS; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; CARBAZOLES; CLINICAL TRIALS AS TOPIC; CYTOKINES; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; LEUKEMIA, MYELOID, ACUTE; PHENYLUREA COMPOUNDS; PYRROLES; STAUROSPORINE; TANDEM REPEAT SEQUENCES;

EID: 80052231301     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0084     Document Type: Article

References (107)

1. Gale RE, Green C, Allen C et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-2784.
2. Kottaridis PD, Gale RE, Frew ME et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752-1759.
3. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia 2003;17: 1738-1752.
4. Thiede C, Steudel C, Mohr B et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-4335.
5. Knapper S, Mills KI, Gilkes AF et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: The induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 2006;108:3494-3503.
6. Levis M, Smith BD, Beran M et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: Clinical response correlates with successful FLT3 inhibition. Blood 2005;106:121a.
7. O'Farrell AM, Foran JM, Fiedler W et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003;9:5465-5476.
8. Yee KW, O'Farrell AM, Smolich BD et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002;100:2941-2949.
9. Cortes J, Foran J, Ghirdaladze D et al. AC220, a potent, selective, second generation FLT3 receptor tyrosine kinase (RTK) inhibitor, in a first-inhuman (FIH) phase 1 AML study. Blood 2009;114:Abstract 636.
10. Rosnet O, Schiff C, Pébusque MJ et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993;82:1110-1119.
11. Small D, Levenstein M, Kim E et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994;91:459-463.
12. Abu-Duhier FM, Goodeve AC, Wilson GA et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001;113:983-988.
13. Agnès F, Shamoon B, Dina C et al. Genomic structure of the downstream part of the human FLT3 gene: Exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene 1994;145:283-288.
14. Carow CE, Kim E, Hawkins AL et al. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12-->q13. Cytogenet Cell Genet 1995;70:255-257.
15. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411:355-365.
16. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994;10:251-337.
17. Dosil M, Wang S, Lemischka IR. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 1993;13:6572-6585.
18. Lavagna-Sévenier C, Marchetto S, Birnbaum D et al. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998;12:301-310.
19. Lavagna-Sévenier C, Marchetto S, Birnbaum D et al. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem 1998;273:14962-14967.
20. Marchetto S, Fournier E, Beslu N et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 1999;13:1374-1382.
21. Mizuki M, Schwable J, Steur C et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003;101:3164-3173.
22. Scheijen B, Ngo HT, Kang H et al. FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004;23:3338-3349.
23. Levis M. Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. Curr Opin Hematol 2005;12:55-61.
24. Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010;36:142-150.
25. Fathi AT, Swinnen I, Rajkhowa T et al. PIM: An integral component of FLT3 signaling and a potential therapeutic target in acute myeloid leukemia. Blood 2010;114:Abstract 1735.
26. Hannum C, Culpepper J, Campbell D et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994;368:643-648.
27. Lyman SD, James L, Johnson L et al. Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 1994;83:2795-2801.
28. Broxmeyer HE, Lu L, Cooper S et al. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995;23:1121-1129.
29. Gotze KS, Ramirez M, Tabor K et al. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood 1998;91:1947-1958.
30. Veiby OP, Jacobsen FW, Cui L et al. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-αand TGF-β. J Immunol 1996;157:2953-2960.
31. McKenna HJ, Stocking KL, Miller RE et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 2000;95:3489-3497.
32. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996;10:588-599.
33. Meierhoff G, Dehmel U, Gruss HJ et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 1995;9: 1368-1372.
34. Birg F, Courcoul M, Rosnet O et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992;80:2584-2593.
35. Carow CE, Levenstein M, Kaufmann SH et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996;87:1089-1096.
36. Rosnet O, Bhring HJ, Marchetto S et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996;10:238-248.
37. Armstrong SA, Kung AL, Mabon ME et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003;3:173-183.
38. Levis M, Allebach J, Tse KF et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002;99: 3885-3891.
39. Quentmeier H, Reinhardt J, Zaborski M et al. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 2003;17:120-124.
40. Yokota S, Kiyoi H, Nakao M et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 1997;11:1605-1609.
41. American Cancer Society Cancer Facts&Figures 2010. Available at http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf. Accessed November 2010.
42. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100:1532-1542.
43. Kiyoi H, Towatari M, Yokota S et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998;12:1333-1337.
44. Nakao M, Yokota S, Iwai T et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10:1911-1918.
45. Yamamoto Y, Kiyoi H, Nakano Y et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001;97:2434-2439.
46. Hayakawa F, Towatari M, Kiyoi H et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624-631.
47. Mizuki M, Fenski R, Halfter H et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-3914.
48. Frohling S, Schlenk RF, Breitruck J et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002;100:4372-4380.
49. Rombouts WJ, Blokland I, Löwenberg B et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000;14:675-683.
50. Schlenk RF, Döhner K, Krauter J et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008; 358:1909-1918.
51. Schnittger S, Schoch C, Dugas M et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002;100:59-66.
52. Böhmer FD, Karagyozov L, Uecker A et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem 2003;278:5148-5155.
53. Lamers MB, Antson AA, Hubbard RE et al. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J Mol Biol 1999;285:713-725.
54. Smith BD, Levis M, Beran M et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004;103:3669-3676.
55. Walters DK, Stoffregen EP, Heinrich MC et al. RNAi-induced downregulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 2005;105:2952-2954.
56. Pratz KW, Cortes J, Roboz GJ et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 2009;113:3938-3946.
57. Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Des 2004;10:1183-1193.
58. Pratz KW, Sato T, Murphy K.M, et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115:1425-1432.
59. Fiedler W, Mesters R, Tinnefeld H et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 2003; 102:2763-2767.
60. Giles FJ, Stopeck AT, Silverman LR et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003;102:795-801.
61. O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605.
62. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006;368:1329-1338.
63. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.
64. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-124.
65. Fiedler W, Serve H, Döhner H et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005;105:986-993.
66. Fiedler W, Krauter J, Götze K et al. A phase I/II study combining sunitinib with standard ara-C/daunorubicin chemotherapy in patients 60 years or older with FLT3 mutated AML. Blood 2010;116:Abstract 3285.
67. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
68. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
69. Christiansen DH, Andersen MK, Desta F et al. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2005;19:2232-2240.
70. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-5480.
71. Auclair D, Miller D, Yatsula V et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 2007;21:439-445.
72. Zhang W, Konopleva M, Shi YX et al. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008;100: 184-198.
73. Pratz KW, Cho E, Levis MJ et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010; 24:1437-1444.
74. Delmonte J, Kantarjian HM, Andreeff M et al. Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood 2007;110:Abstract 893.
75. Lee SH, Paietta E, Racevskis J et al. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol 2009;84:701-702.
76. Safaian NN, Czibere A, Bruns I et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. Leuk Res 2009;33:348-350.
77. Metzelder S, Wang Y, Wollmer E et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation. Blood 2009;113:6567-6571.
78. Metzelder S, Finck A, Fey M et al. Sorafenib monotherapy is effective in relapsed and refractory Flt3-ITD positive acute myeloid leukemia, particularly after allogenic stem cell transplantation. Blood 2010;116:Abstract 3314.
79. Sharma MR, Ravandi F, Chiattone A et al. Treatment of FLT3-ITD positive AML relapsing after allogeneic hematopoietic stem cell transplant (HSCT) with sorafenib. Blood 2010;116:Abstract 3471.
80. Ravandi F, Cortes JE, Jones D et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010;28:1856-1862.
81. Serve H, Wagner R, Sauerland C et al. Sorafenib in combination with standard induction and consolidation therapy In elderlyAMLpatients: Results from a randomized, placebo-controlled phase II trial. Blood 2010;116: Abstract 333.
82. Kelly LM, Yu JC, Boulton CL et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002;1:421-432.
83. Griswold IJ, Shen LJ, La Rosée P et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood 2004; 104:2912-2918.
84. DeAngelo DJ, Stone RM, Heaney ML et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics. Blood 2006;108:3674-3681.
85. Schittenhelm MM, Kampa KM, Yee KW et al. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell Cycle 2009;8:2621-2630.
86. DeAngelo DJ, Amrein PC, Kovacsovics TJ et al. Phase 1/2 study of tandutinib (MLN518) plus standard induction chemotherapy in newly diagnosed acute myelogenous leukemia (AML). Blood 2006;108:Abstract 158.
87. Camoratto AM, Jani JP, Angeles TS et al. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer 1997;72:673-679.
88. Hexner EO, Serdikoff C, Jan M et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008;111:5663-5671.
89. Strock CJ, Park JI, Rosen M et al. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 2003;63:5559-5563.
90. Marshall JL, Kindler H, Deeken J et al. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 2005;23:31-37.
91. Levis M, Brown P, Smith BD et al. Plasma inhibitory activity (PIA): A pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood 2006;108:3477-3483.
92. Knapper S, Burnett AK, Littlewood T et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 2006;108:3262-3270.
93. Levis M, Pham R, Smith BD et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: Sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004;104:1145-1150.
94. Levis M, Ravandi F, Wang ES et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutantAMLpatients in first relapse. Blood 2009;114:Abstract 788.
95. Sato T, Yang X, Knapper S et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011;117:3286-3293.
96. Knapper S, Burnett AK, Hills RK et al. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may influence relapse risk. Blood 2009;114:Abstract 789.
97. Fabbro D, Ruetz S, Bodis S et al. PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
98. Propper DJ, McDonald AC, Man A et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol 2001;19: 1485-1492.
99. Weisberg E, Boulton C, Kelly LM et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002;1:433-443.
100. Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005;105:54-60.
101. Stone RM, Fischer T, Paquette R et al. A phase 1b study of midostaurin (PKC412) in combination with daunorubicin and cytarabine induction and high-dose cytarabine consolidation in patients under age 61 with newly diagnosed de novo acute myeloid leukemia: Overall survival of patients whose blasts have FLT3 mutations is similar to those with wild-type FLT3. Blood 2009;114:Abstract 634.
102. Fischer T, Stone RM, Deangelo DJ et al. Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multitargeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010;28:4339-4345.
103. Shiotsu Y, Kiyoi H, Ishikawa Y et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-1617.
104. Cortes J, Roboz GJ, Kantarjian H et al. A phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Blood 2008;112:Abstract 2967.
105. Chao Q, Sprankle KG, Grotzfeld RM et al. Identification of N-(5-tertbutyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem 2009;52:7808-7816.
106. Zarrinkar PP, Gunawardane RN, Cramer MD et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114:2984-2992.
107. Cortes J, Ghirdaladze D, Foran JM et al. Phase 1 AML study of AC220, a potent and selective second generation FLT3 receptor tyrosine kinase inhibitor. Blood 2008;112:Abstract 767.